Immunome (NASDAQ:IMNM) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Immunome (NASDAQ:IMNM) from a sell rating to a strong sell rating in a research note released on Saturday.

A number of other equities analysts also recently issued reports on the company. Wedbush increased their price objective on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday. Citigroup restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Truist Financial increased their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Leerink Partners lowered their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Immunome Stock Performance

Immunome stock opened at $27.20 on Friday. The stock’s 50 day simple moving average is $22.20 and its two-hundred day simple moving average is $22.24. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -10.75 and a beta of 2.08. Immunome has a fifty-two week low of $8.66 and a fifty-two week high of $28.62.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, analysts predict that Immunome will post -2.3 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Max Rosett sold 60,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. This represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00. Following the transaction, the insider owned 15,805 shares of the company’s stock, valued at $313,729.25. The trade was a 77.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 682,310 shares of company stock worth $15,675,566 over the last three months. 7.21% of the stock is owned by corporate insiders.

Institutional Trading of Immunome

Several institutional investors have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. increased its stake in Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. BlackRock Inc. bought a new position in shares of Immunome in the second quarter worth approximately $186,588,000. Vanguard Group Inc. grew its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after buying an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the last quarter. Finally, State Street Corp increased its position in shares of Immunome by 37.9% during the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after acquiring an additional 1,064,027 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.